- Home
- CORT
as 09-10-2025 3:31pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $139.00 | AVG Volume (30 days): | 640.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.11 | EPS Growth: | -1.47 |
| 52 Week Low/High: | $34.34 - $117.33 | Next Earning Date: | 10-29-2025 |
| Revenue: | $716,080,000 | Revenue Growth: | 25.71% |
| Revenue Growth (this year): | 30.62% | Revenue Growth (next year): | 37.68% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lyon Joseph Douglas | CORT | See Remarks | Sep 2 '25 | Sell | $70.50 | 5,000 | $351,247.44 | 10,171 | |
| Maduck Sean | CORT | See Remarks | Sep 2 '25 | Sell | $70.61 | 20,000 | $1,409,828.00 | 12,611 | |
| Guyer William | CORT | Chief Development Officer | Sep 2 '25 | Sell | $70.62 | 20,000 | $1,409,848.25 | 5,487 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Sep 2 '25 | Sell | $70.76 | 40,000 | $2,821,033.45 | 2,821,370 | |
| Robb Gary Charles | CORT | Chief Business Officer | Aug 22 '25 | Sell | $71.27 | 2,326 | $165,774.02 | 16,038 | |
| Swisher Daniel N JR | CORT | N/A | Aug 11 '25 | Sell | $72.30 | 2,200 | $159,060.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Aug 8 '25 | Sell | $71.77 | 35,007 | $2,512,452.39 | 5,487 | |
| Robb Gary Charles | CORT | Chief Business Officer | Jun 16 '25 | Sell | $70.77 | 3,185 | $225,402.45 | 16,038 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Corcept Therapeutics Insider Sold Shares Worth $2,821,033, According to a Recent SEC Filing
Zacks
2 months ago
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
StockStory
2 months ago
5 Insightful Analyst Questions From Corcept’s Q1 Earnings Call
Argus Research
3 months ago
CORT: Raising target price to $84.00
Insider Monkey
3 months ago
Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint
Business Wire
3 months ago
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
Simply Wall St.
3 months ago
June 2025's High Insider Ownership Growth Stocks
Simply Wall St.
3 months ago
Do Its Financials Have Any Role To Play In Driving Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Up Recently?
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.